Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Yoshihiko Shimokawa"'
Autor:
Makoto Matsumoto, Hiroyuki Hashizume, Tatsuo Tomishige, Masanori Kawasaki, Hidetsugu Tsubouchi, Hirofumi Sasaki, Yoshihiko Shimokawa, Makoto Komatsu
Publikováno v:
PLoS Medicine, Vol 3, Iss 11, p e466 (2006)
BACKGROUND: Tuberculosis (TB) is still a leading cause of death worldwide. Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result. Today's TB
Externí odkaz:
https://doaj.org/article/a27d8ae295b54f30a1f9c0f3ff5c6d19
Autor:
Takamune Yokoyama, Ken Uchida, Ryosuke Yamachi, Takahisa Tanaka, Yuta Saito, Yoshihiko Shimokawa
Publikováno v:
ACS Applied Nano Materials. 1:3886-3894
To demonstrate the feasibility of a fast, low-energy breath diagnosis method, hydrogen sensors utilizing Joule self-heating were developed. The sensors consisted of suspended graphene films functionalized with Pd nanoparticles as sensing layers and u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af2963f1f191f2b061a588acca7a0dd1
https://doi.org/10.1021/acsanm.8b00667
https://doi.org/10.1021/acsanm.8b00667
Autor:
Katsunori Sasahara, Noriaki Yoda, Hiroyuki Sasabe, Yoshihiko Shimokawa, Ken Umehara, Masakazu Shibata, Mitsunari Suzuki
Publikováno v:
Biopharmaceutics & Drug Disposition. 38:301-312
Delamanid (OPC-67683, Deltyba™, nitro-dihydro-imidazooxazoles derivative) is approved for the treatment of adult pulmonary multidrug-resistant tuberculosis. The absorption, distribution and excretion of delamanid-derived radioactivity were investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8462605b89ec78754dbe3dddda90d5ef
https://doi.org/10.1002/bdd.2064
https://doi.org/10.1002/bdd.2064
Autor:
Katsunori Sasahara, Yukihiro Hirao, Masakazu Shibata, Kazuyoshi Kitano, Ken Umehara, Noriyuki Koyama, Yoshihiko Shimokawa
Publikováno v:
Drug Metabolism and Disposition. 43:1267-1276
Delamanid, a new anti-tuberculosis drug, is metabolized to M1, a unique metabolite formed by cleavage of the 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole moiety, in plasma albumin in vitro. The metabolic activities in dogs and humans are higher than tho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d811e5c1e2f2f21eac46682e86c0da
https://doi.org/10.1124/dmd.115.064527
https://doi.org/10.1124/dmd.115.064527
Autor:
Ruri Kikura-Hanajiri, Yosuke Demizu, Nahoko Uchiyama, Takashi Hakamatsuka, Yoshihiko Shimokawa, Yukihiro Goda
Publikováno v:
Forensic Toxicology
Six new psychoactive substances were identified together with two other substances (compounds 1–8) in illegal products by our ongoing survey in Japan between January and July 2014. A new synthetic cannabinoid, FDU-NNEI [1-(4-fluorobenzyl)-N-(naphth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f31dd0d9f0f41245fa255399a0fd4820
https://doi.org/10.1007/s11419-015-0268-7
https://doi.org/10.1007/s11419-015-0268-7
Publikováno v:
American Journal of Analytical Chemistry. :98-105
Sensitive and selective liquid chromatography-tandem mass spectrometry methods have been developed and validated for the determination of delamanid in mouse plasma and lung. Sample preparation involved liquid-liquid extraction with diethyl ether for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b925d77a672241464fff38f3231fab63
https://doi.org/10.4236/ajac.2015.62009
https://doi.org/10.4236/ajac.2015.62009
Autor:
Nahoko Uchiyama, Maiko Kawamura, Ruri Kikura-Hanajiri, Yoshihiko Shimokawa, Takashi Hakamatsuka
Publikováno v:
Forensic Toxicology. 32:266-281
From November 2013 to May 2014, 19 newly distributed designer drugs were identified in 104 products in our ongoing survey of illegal products in Japan. The identified compounds included 8 synthetic cannabinoids, FUB-PB-22 (1), 5-fluoro-NNEI indazole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::429810371ac645344c2b0cdb687e7ea5
https://doi.org/10.1007/s11419-014-0238-5
https://doi.org/10.1007/s11419-014-0238-5
Autor:
Nahoko Uchiyama, Yoshihiko Shimokawa, Satoru Matsuda, Maiko Kawamura, Ruri Kikura-Hanajiri, Yukihiro Goda
Publikováno v:
Forensic Toxicology. 32:105-115
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dec72e44fd8a8a527ea74cc3dc620e73
https://doi.org/10.1007/s11419-013-0217-2
https://doi.org/10.1007/s11419-013-0217-2
Autor:
Masakazu, Shibata, Yoshihiko, Shimokawa, Katsunori, Sasahara, Noriaki, Yoda, Hiroyuki, Sasabe, Mitsunari, Suzuki, Ken, Umehara
Publikováno v:
Biopharmaceuticsdrug disposition. 38(4)
Delamanid (OPC-67683, Deltyba™, nitro-dihydro-imidazooxazoles derivative) is approved for the treatment of adult pulmonary multidrug-resistant tuberculosis. The absorption, distribution and excretion of delamanid-derived radioactivity were investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43cc0f2590106d7ac9cbb6f88719f5b6
https://pubmed.ncbi.nlm.nih.gov/28092695
https://pubmed.ncbi.nlm.nih.gov/28092695
Autor:
Hiroyuki Sasabe, Kenta Hashizume, Yoshihiro Ohzone, Masakazu Shibata, Yoshihiko Shimokawa, Eiji Kashiyama, Yusuke Hamasako, Ken Umehara
Delamanid (Deltyba, OPC-67683) is the first approved drug in a novel class of nitro-dihydro-imidazooxazoles developed for the treatment of multidrug-resistant tuberculosis. Patients with tuberculosis require treatment with multiple drugs, several of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eefdace9a19b2c2e1ec90652636b947f
https://europepmc.org/articles/PMC4879383/
https://europepmc.org/articles/PMC4879383/
